A multi-center, double-blind, randomized, parallel group, placebo-controlled 24-week study to investigate glycemic parameters of efficacy and safety/tolerability in patients with type 2 diabetes mellitus randomized to two dose levels of RO4998452, or placebo.

Trial Profile

A multi-center, double-blind, randomized, parallel group, placebo-controlled 24-week study to investigate glycemic parameters of efficacy and safety/tolerability in patients with type 2 diabetes mellitus randomized to two dose levels of RO4998452, or placebo.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2010

At a glance

  • Drugs Tofogliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 04 Aug 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top